Atalyd
6-Methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 9568614.
Registration
- Applicants
- 1
- Registrations
- 3
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cipla Medpro (Pty) Ltd | Atalyd | 2,5, 5, 10 | 560158.155, 590071.069, 590072.070 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Atalyd 10 granules EACH SACHET CONTAINS ESOMEPRAZOLE MAGNESIUM DIHYDRATE 10,0 mg | 10Granules | 560158.15556/11.4.3/0158.155 | Registered | Not determined | None |
| Atalyd 2,5 granules EACH SACHET CONTAINS: ESOMEPRAZOLE MAGNESIUM DIHYDRATE 2,5 mg | 2,5Granules | 590071.06959/11.4.3/0071.069 | Registered | Not determined | None |
| Atalyd 5 granules EACH SACHET CONTAINS: ESOMEPRAZOLE MAGNESIUM DIHYDRATE 5,0 mg | 5Granules | 590072.07059/11.4.3/0072.070 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Esomeprazole
- except when indicated for the temporary, short-term relief of heartburn and hyperacidity, subject to:
- a maximum daily dose of 20 milligrams
- a maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 6239 to 6244
S2: Esomeprazole
- when indicated for the temporary, short-term relief of heartburn and hyperacidity subject to:
- a maximum daily dose of 20 milligrams
- a maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 1921 to 1925
S1: Magnesium
- in oral preparations or mixtures containing more than 250 mg of Magnesium per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 815 to 816
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.